生物活性 | |||
---|---|---|---|
描述 | CPI-1189, an oral inhibitor of TNF-α release, also impedes the phosphorylation of p38. It has the capability to inhibit apoptosis and is utilized in research related to HIV and neurological diseases[1][2][3][4][5]. CPI-1189, at a concentration of 100 nM and a duration of 1 hour, can effectively prevent oxidative damage and neuronal cell death in SH-SY5Y cells induced by Oxygen glucose deprivation (OGD)/re-oxygenation (OGDR)[3]. CPI-1189, at a concentration of 10 nM and over a period of 2 hours, inhibits the phosphorylation of P38-mitogen-activated protein kinase induced by interleukin1β[4]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
4.27mL 0.85mL 0.43mL |
21.34mL 4.27mL 2.13mL |
42.68mL 8.54mL 4.27mL |
参考文献 |
---|
[1]Müller T. CPI-1189. Centaur. Curr Opin Investig Drugs. 2002 Dec;3(12):1763-7. |